When a frontline officer encounters an unknown substance in the field, they need to know what it is — fast, accurately, and without sending it to a lab. That's the problem Spectra Plasmonics is built around.
The company's product, Amplifi ID, is a rapid chemical identification platform designed for exactly that moment. Its primary users today are law enforcement and public health agencies using it to identify unknown substances including fentanyl and other highly potent drugs in the field. Founder Malcolm Eade describes Spectra simply: "We're a chemical intelligence company. The mission is providing accurate, rapid chemical identification at the point where a critical decision needs to be made."
Spectra is based in Kingston, Ontario, but the B.C. ecosystem has played an outsized role in shaping the company. A West Coast-based VC encouraged the team to apply to CDL-Vancouver, drawn by the quality of health and medtech mentors there. Getting in opened doors the team wouldn't have found on their own — including exposure to agencies that had been dealing with the fentanyl crisis for years. "Vancouver was ground zero for the fentanyl surge in Canada," Eade says. "Getting exposure to agencies that had been living with that problem for years genuinely broadened our thinking."
One thing Eade is keen to convey is that the public health and defence threat landscapes are less separate than most people assume. Fentanyl analogs, he notes, have been deployed as incapacitating agents by state actors and investigated as chemical weapons by state programs. The platform's ability to expand its detection library without hardware changes matters in a threat environment that evolves faster than traditional procurement cycles. Spectra's defence exposure is real, Eade says, but currently narrow — falling under CBRN detection rather than broader defence health solutions.
On procurement, Eade is candid. Spectra has signed cooperative research agreements with US federal agencies and been invited to demonstrate at US military exercises — relationships that moved faster than equivalent conversations at home. "The gap isn't talent or technology. It's procurement culture and the willingness to adopt domestic innovation."
The UBC Sauder Scale Up Program, Eade says, tackles something genuinely underserved in the Canadian ecosystem: what happens after early traction, when founder-led growth hits its ceiling. CDL opened West Coast relationships and accelerated early validation. Scale Up addressed something different. "It accelerates the founder-to-CEO evolution," he says. "I think it's one of the reasons promising deep tech companies here plateau when they shouldn't."
Spectra Plasmonics is one of eight ventures in the UBC Sauder Scale Up Program's pilot cohort.